Skip to content
Screener

BioMarin Pharmaceuticals BMRN Q4 2025 Annual earnings

Reported February 23, 2026 · After market close

Revenue$874.6MBeat by $40.8M
EPS-$0.24Miss by $0.41
Revenue estimate$833.7M
EPS estimate$0.17

Next report

Oct 26, 2026 (in a month)
Revenue estimate$1.0B
EPS estimate$1.35

Financials

Q4 2025

Income statement

See full
Revenue$874.6M+17.0%
Gross profit$598.9M-2.0%

Balance sheet

See full
Cash & equivalents$1.3B+39.1%
Total debt$642.9M+1,556%
Total equity$6.1B+7.6%
Total assets$7.6B+8.7%

Cash flow

See full
Operating cash flow$99.6M-46.3%
CapEx$40.7M+109%
Free cash flow$58.9M-64.5%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$11.42B-8.9%
Enterprise value$10.75B-7.5%
P/S3.5×-0.8×

Profitability

See full
Gross margin77.7%-1.9pp
FCF margin22.5%+5.4pp

Returns & leverage

See full
Debt / equity0.1×+0.1×
Current ratio5.2×-0.1×

Segments

By product

See full
VOXZOGO$273.4M+31.1%
VIMIZIM$205.5M+7.6%
PALYNZIQ$125.3M+24.8%
NAGLAZYME$120.2M+9.3%
BRINEURA$49.4M+3.5%

By segment

See full
Reportable Segment$874.6M+17.0%

FAQ

When did BioMarin Pharmaceuticals report Q4 2025 earnings?
BioMarin Pharmaceuticals (BMRN) reported Q4 2025 earnings on February 23, 2026 after market close.
What were BioMarin Pharmaceuticals's Q4 2025 revenue and EPS?
BioMarin Pharmaceuticals reported revenue of $874.6M and eps of $-0.24 for Q4 2025.
Did BioMarin Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $833.7M by $40.8M. EPS missed the consensus estimate of $0.17 by $0.41.
How did BioMarin Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 18.5% from $738.2M a year earlier.
Where can I find BioMarin Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001048477-26-000002) and the 10-K periodic report (0001048477-26-000004) directly on SEC EDGAR. The filing index links above go to sec.gov.